Vyvanse Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" Actually Means for a Schedule II Drug Like Vyvanse

Compassionate use, formally called "expanded access" by the FDA, is a pathway that allows patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials. The FDA describes expanded access as intended for patients "who have no comparable or satisfactory alternative therapy" (FDA Expanded Access Guidance, 2023).

Vyvanse is not investigational. It has been FDA-approved since 2007 for ADHD and since 2015 for moderate-to-severe binge eating disorder. Because approved versions exist, including a generic, the legal threshold for a compassionate use request is extremely high.

When Expanded Access Might Still Apply

There are narrow scenarios where an expanded-access request for lisdexamfetamine could be considered:

• A patient enrolled in a clinical trial studying lisdexamfetamine for an off-label indication (for example, treatment-resistant depression) who experiences clinical benefit and needs continued access after the trial closes.
• A pediatric patient below age 6 where no other stimulant has worked and a physician documents medical necessity.
• International patients in countries where lisdexamfetamine is not approved, though this falls under each country's own regulatory framework rather than the U.S. FDA process.

In all three cases, the prescribing physician must submit an Expanded Access IND (Investigational New Drug) application directly to the FDA. The FDA's Office of Oncology Products and Office of Neuroscience handle most CNS requests. The application requires a treatment protocol, informed consent documentation, and Institutional Review Board approval for individual patient access (21 CFR Part 312, Subpart I).

What Takeda's Current Policy Looks Like

Takeda does not maintain a publicly listed open expanded-access protocol for Vyvanse in 2026. Physicians may contact Takeda Medical Information at 1-877-TAKEDA-7 to inquire about individual compassionate-use requests on a case-by-case basis. Given that FDA-approved generic lisdexamfetamine has been commercially available since 2023, Takeda is unlikely to approve such requests without extraordinary clinical justification.

The FDA Expanded Access Process: A Step-by-Step Overview

For the rare patient who qualifies, here is how the formal expanded-access process works for a drug like lisdexamfetamine.

Step 1: Physician Initiates the Request

The treating physician, not the patient, must contact the drug manufacturer first. For Vyvanse, that means contacting Takeda to request access and obtain a letter of authorization. Without manufacturer cooperation, the FDA will not approve an individual patient IND.

Step 2: Submit FDA Form 3926

Individual patient expanded access requires FDA Form 3926, which the physician submits to the relevant FDA center (CDER for lisdexamfetamine). The FDA typically responds to emergency requests within 24 hours and non-emergency requests within 30 days (FDA, 2023).

Step 3: IRB Review

An Institutional Review Board must approve the treatment protocol. For single-patient access, many IRBs expedite this review. The physician's affiliated hospital or clinic typically manages this step.

Step 4: Ongoing Safety Reporting

Once access is granted, the physician must submit annual safety reports to the FDA and report any serious adverse events within 15 calendar days. Lisdexamfetamine's known adverse event profile includes cardiovascular effects (elevated heart rate and blood pressure), insomnia, decreased appetite, and rare serious psychiatric events. The full prescribing information is available at FDA AccessData.

Generic Lisdexamfetamine: The Most Practical "Access" Solution for Most Patients

For the overwhelming majority of patients who cannot afford brand Vyvanse, the practical answer is not compassionate use. It is generic lisdexamfetamine.

The FDA approved the first generic lisdexamfetamine dimesylate capsules in 2023. Multiple manufacturers now produce the drug. Generic versions are therapeutically equivalent to Vyvanse by FDA standards, meaning they contain the same active ingredient at the same labeled dose, with bioequivalence demonstrated in pharmacokinetic studies (FDA Orange Book).

Generic Pricing vs. Brand Pricing

Retail prices vary by pharmacy, but generic lisdexamfetamine typically costs $80-$140 per 30-count supply at major U.S. Pharmacies as of early 2026, compared to $380-$420 for brand Vyvanse at the same count and dose. Using a discount card service (GoodRx, RxSaver, Cost Plus Drugs) can bring generic costs lower at specific pharmacies.

A 2022 JAMA study analyzing drug pricing found that generic entry reduces brand prices by an average of 85% within two years of first generic approval (Hernandez et al., JAMA, 2022). Lisdexamfetamine has followed a similar pattern.

Formulary Considerations

Some insurance plans still require prior authorization for generic lisdexamfetamine because it is a Schedule II stimulant. If a prior authorization is denied, the appeals process should cite the patient's treatment history, failed trials of alternative stimulants, and the prescriber's clinical rationale. The American Academy of Family Physicians recommends that prior authorization criteria be clinically based and not solely cost-driven (AAFP Policy on Prior Authorization, 2022).

Takeda Patient Assistance and Savings Programs

Takeda operates two main programs that reduce Vyvanse costs for eligible patients. Understanding which one applies to a given patient situation is the first step a prescriber or care coordinator should take before exploring expanded access.

Takeda Vyvanse Savings Card (Commercially Insured Patients)

Commercially insured patients who are not enrolled in any federal or state government healthcare program may use the Takeda Vyvanse Savings Card. As of early 2026, eligible patients may pay as little as $30 per monthly prescription, with Takeda covering the remainder up to a defined maximum per fill. The program has an annual benefit cap, and patients must re-enroll each calendar year.

Patients enroll at the Takeda patient support website or by calling Takeda's patient support line. The savings card is not valid for patients using Medicare, Medicaid, TRICARE, or any state-funded program, because federal anti-kickback statutes prohibit manufacturer subsidies from reducing government program cost-sharing.

Takeda Together with Vyvanse Patient Assistance Program (Uninsured/Underinsured)

Patients who are uninsured, underinsured, or do not meet income thresholds for commercial savings may apply to Takeda's patient assistance program (PAP). This program provides Vyvanse at no cost or reduced cost based on household income and insurance status. Typical eligibility requirements include:

• U.S. Residency and citizenship or lawful presence.
• Annual household income at or below 400-600% of the Federal Poverty Level (exact threshold changes annually).
• No current prescription drug insurance coverage for Vyvanse, or documented insurance denial.

The prescribing physician must co-sign the PAP application. Processing typically takes 2-4 weeks. For patients in urgent need, Takeda may provide a 30-day bridge supply while the application is reviewed.

Comparing the Two Programs

| Situation | Best Program | |---|---| | Has commercial insurance, high copay | Savings Card | | Uninsured, income <400% FPL | Patient Assistance Program | | On Medicare Part D | Neither (federal exclusion applies) | | On Medicaid | Neither (federal exclusion applies) |

HSA and FSA Eligibility for Vyvanse

Vyvanse is eligible for payment through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). Both brand and generic lisdexamfetamine qualify as an HSA/FSA-eligible medical expense under IRS Publication 502 because the drug requires a valid prescription from a licensed prescriber (IRS Publication 502, 2024).

How HSA/FSA Payment Works at the Pharmacy

Most major pharmacy chains (CVS, Walgreens, Rite Aid, Walmart Pharmacy) accept HSA and FSA debit cards directly at point of sale. The patient presents their HSA/FSA card and the transaction is processed like any debit payment. No reimbursement paperwork is required for in-person pharmacy transactions.

For mail-order pharmacies, note that Schedule II controlled substances including lisdexamfetamine cannot legally be dispensed via mail order in most U.S. States. Federal law under the Controlled Substances Act (21 U.S.C. 829) requires a new written prescription for each Schedule II dispensing, and most states interpret this as requiring in-person pickup. Check your state's pharmacy board rules.

Stacking HSA/FSA With Takeda Savings Card

A commercially insured patient may not stack the Takeda Savings Card on top of HSA/FSA funds for the same transaction. The Savings Card acts as a secondary payer after insurance; the patient then pays the remaining copay (potentially $30) using HSA/FSA dollars. The $30 paid from an HSA is still a qualified medical expense. This is a legal and commonly used approach.

Other Legitimate Ways to Reduce Vyvanse Costs

Pharmacy Discount Cards and Cash-Pay Pricing

Discount card programs (not insurance) negotiate cash-pay rates with pharmacies. These cannot be combined with insurance but can be used instead of insurance if the discount price is lower than the insured copay. For generic lisdexamfetamine specifically, cash-pay rates through discount programs at some pharmacies can fall below $60 per 30-count supply.

The federal government's 340B Drug Pricing Program allows eligible health centers (federally qualified health centers, certain hospitals) to purchase outpatient drugs at significantly reduced prices. A patient whose prescriber practices at a 340B-eligible entity may access lisdexamfetamine at 340B pricing, which can be substantially below retail. The Health Resources and Services Administration maintains a searchable database of 340B-covered entities (HRSA 340B Database).

Dose Optimization

Lisdexamfetamine is a prodrug converted to d-amphetamine in the body. All capsule strengths (20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg) are priced approximately the same per capsule. If a patient takes 40 mg daily, prescribing 70 mg capsules and having the patient open and split the powder to take a measured portion is sometimes discussed, but the FDA does not recommend this approach because accurate dose splitting of capsule powder is not reliable. A physician should not recommend dose splitting for Schedule II stimulants.

State Pharmaceutical Assistance Programs

Several states operate pharmaceutical assistance programs for residents who do not qualify for Medicaid but still face high drug costs. New Jersey's Pharmaceutical Assistance to the Aged and Disabled (PAAD), Pennsylvania's PACE program, and New York's EPIC program are three examples. Eligibility is income-based and typically targets older adults and people with disabilities. The National Conference of State Legislatures maintains a summary of state drug assistance programs that a social worker or care coordinator can reference.

Special Populations: Pediatric Patients and Pregnancy

Pediatric Compassionate Use Considerations

Vyvanse is FDA-approved for ADHD in patients as young as 6 years. Lisdexamfetamine has not been studied or approved in children under 6, and no pediatric compassionate-use protocol is currently open. The American Academy of Pediatrics 2019 ADHD clinical practice guideline recommends behavior therapy as first-line treatment for children under 6, with medication reserved for cases where behavior therapy has failed (AAP ADHD Guideline, 2019). Prescribing lisdexamfetamine off-label to a child under 6 would require extraordinary justification and careful risk-benefit documentation.

Pregnancy and Lactation

Lisdexamfetamine is FDA Pregnancy Category C (pre-2015 labeling) and carries a Pregnancy and Lactation Labeling Rule (PLLR) designation noting risk of premature delivery, low birth weight, and neonatal withdrawal symptoms with amphetamine use during pregnancy. The drug is present in breast milk. Patients who are pregnant or breastfeeding should discuss risk-benefit with their physician before continuing lisdexamfetamine. There is no expanded-access pathway specific to pregnant patients for Vyvanse.

When to Contact a Physician About Expanded Access

A patient or caregiver should raise the topic of expanded access with their physician if:

• They have exhausted all approved stimulant and non-stimulant ADHD medications and have documented treatment failure with each.
• They are participating in a clinical trial of lisdexamfetamine for an investigational indication and the trial is closing.
• They reside outside the United States in a country where lisdexamfetamine is not approved and their physician needs to request importation under the FDA's personal importation policy.

In any of these cases, the physician initiates the process, not the patient. The FDA's expanded access inbox for non-emergency requests is druginfo@fda.hhs.gov, and the FDA's Office of Neuroscience handles CNS drug access requests.

The Endocrine Society and American Psychiatric Association do not maintain separate expanded-access registries for stimulant medications. The FDA pathway described above is the only formal mechanism in the United States.

What the Clinical Evidence Says About Lisdexamfetamine's Efficacy

Access programs matter only if the drug works. The evidence base for lisdexamfetamine is well-established.

For ADHD, a 2019 Cochrane systematic review analyzing 8 randomized controlled trials (N=2,027) found lisdexamfetamine significantly reduced ADHD symptom scores compared to placebo, with a standardized mean difference of 0.75 (95% CI 0.64 to 0.86), a large effect size (Punja et al., Cochrane, 2016, updated 2019).

For binge eating disorder, the key Phase 3 trials (SPD489-343 and SPD489-344, combined N=773) showed lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week by approximately 3.87 days compared to 2.29 days for placebo over 12 weeks (P<0.001) (Hudson et al., International Journal of Eating Disorders, 2017). These data supported the 2015 FDA approval.

A 2021 meta-analysis published in JAMA Psychiatry (N=5,765 across 19 trials) confirmed that amphetamine-class stimulants, including lisdexamfetamine, produce meaningful reductions in adult ADHD symptom severity, with an effect size of 0.79 for amphetamines versus 0.49 for non-stimulant alternatives (Cortese et al., JAMA Psychiatry, 2018).

The clinical director of HealthRX's psychiatric care team notes: "For patients who have failed methylphenidate-class drugs and at least one non-stimulant like atomoxetine, lisdexamfetamine is often the appropriate next step. The goal should be accessing it at a sustainable cost, whether through generic substitution, the Takeda savings program, or HSA dollars, rather than pursuing the compassionate-use pathway, which is not designed for this situation."